Skip to main content

nivolumab (Opdivo®)

 

Status: Excluded due to NICE appraisal

Product meets AWMSG exclusion criteria due to NICE appraisal ID1136: Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

Medicine details

Medicine name nivolumab (Opdivo®)
Formulation Concentrate for solution for infusion
Reference number 3317
Indication

Treatment of previously treated proficient mismatch repair (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer patients

Company Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter Malignant disease & immunosuppression
Submission type N/A
Status Excluded due to NICE appraisal
NICE guidance

ID1136: Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

Follow AWTTC: